BioSpace News Archive

Company Demonstrates Initial Comparability Between TARA-002 and OK-432, Advancing to Final GMP Comparability Runs

The Phase 1/2 Open-Label, Single Arm, Multi-Center Clinical Trial is Testing Kamada’s Hyperimmune IgG Product in Hospitalized, Non-Ventilated COVID-19 Patients with Pneumonia

Bio-Techne Corporation announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with Hall of Famer and baseball’s all-time “Iron Man”, Cal Ripken Jr. This year marks 25 years since Ripken played in his 2,131st consecutive game, eclipsing the thought to be unbreakable record of 2,130 set by the legendary Lou Gehrig.

Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal healthcare, announced that President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will be presenting at the Morgan Stanley Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 2:00 p.m. Eastern Time.

Biomica’s, a subsidiary of Evogene Ltd., live biotherapeutic drug candidate BMC128 administered in combination with Immune Checkpoint Inhibitors (ICI) significantly improved anti-tumor activity. Proof-of-concept first-in-man studies expected next year.

ANANDA Scientific Inc., a biotech pharma company, announced that Sohail Zaidi has been appointed as ANANDA’s new President.

Schrödinger, whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, announced that members of the management team will participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference at 12:30 p.m. ET on Tuesday, September 15, 2020.

First CAR T therapy leveraging combination of cell intrinsic PD1DNR checkpoint inhibition and 1XX CAR signaling technologies to enter the clinic

Announces Decision to Fund Clinical Manufacture of Ficlatuzumab for Potential Phase 3 Study and Update to Biodesix Partnership

CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the U.S.-based “CytoSorb Therapy in COVID-19 ICU Patients,” Registry, is now live and actively enrolling patients.